Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10376319" target="_blank" >RIV/00216208:11130/18:10376319 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/18:10376319

Výsledek na webu

<a href="https://doi.org/10.1038/s41416-018-0098-6" target="_blank" >https://doi.org/10.1038/s41416-018-0098-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41416-018-0098-6" target="_blank" >10.1038/s41416-018-0098-6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

Popis výsledku v původním jazyce

BACKGROUND: In neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA), occasionally shows intratumoural heterogeneity (ITH), i.e. coexistence of MYCN-amplified and non-MYCN-amplified tumour cell clones, called heterogeneous MNA (hetMNA). Prognostication and therapy allocation are still unsolved issues. METHODS: The SIOPEN Biology group analysed 99 hetMNA NBs focussing on the prognostic significance of MYCN ITH. RESULTS: Patients &lt;18 months (18 m) showed a better outcome in all stages as compared to older patients (5-year OS in localised stages: &lt;18 m: 0.95 +/- 0.04, &gt;18 m: 0.67 +/- 0.14, p = 0.011; metastatic: &lt;18 m: 0.76 +/- 0.15, &gt;18 m: 0.28 +/- 0.09, p = 0.084). The genomic &apos;background&apos;, but not MNA clone sizes, correlated significantly with relapse frequency and OS. No relapses occurred in cases of only numerical chromosomal aberrations. Infiltrated bone marrows and relapse tumour cells mostly displayed no MNA. However, one stage 4s tumour with segmental chromosomal aberrations showed a homogeneous MNA in the relapse. CONCLUSIONS: This study provides a rationale for the necessary distinction between heterogeneous and homogeneous MNA. HetMNA tumours have to be evaluated individually, taking age, stage and, most importantly, genomic background into account to avoid unnecessary upgrading of risk/overtreatment, especially in infants, as well as in order to identify tumours prone to developing homogeneous MNA.

Název v anglickém jazyce

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

Popis výsledku anglicky

BACKGROUND: In neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA), occasionally shows intratumoural heterogeneity (ITH), i.e. coexistence of MYCN-amplified and non-MYCN-amplified tumour cell clones, called heterogeneous MNA (hetMNA). Prognostication and therapy allocation are still unsolved issues. METHODS: The SIOPEN Biology group analysed 99 hetMNA NBs focussing on the prognostic significance of MYCN ITH. RESULTS: Patients &lt;18 months (18 m) showed a better outcome in all stages as compared to older patients (5-year OS in localised stages: &lt;18 m: 0.95 +/- 0.04, &gt;18 m: 0.67 +/- 0.14, p = 0.011; metastatic: &lt;18 m: 0.76 +/- 0.15, &gt;18 m: 0.28 +/- 0.09, p = 0.084). The genomic &apos;background&apos;, but not MNA clone sizes, correlated significantly with relapse frequency and OS. No relapses occurred in cases of only numerical chromosomal aberrations. Infiltrated bone marrows and relapse tumour cells mostly displayed no MNA. However, one stage 4s tumour with segmental chromosomal aberrations showed a homogeneous MNA in the relapse. CONCLUSIONS: This study provides a rationale for the necessary distinction between heterogeneous and homogeneous MNA. HetMNA tumours have to be evaluated individually, taking age, stage and, most importantly, genomic background into account to avoid unnecessary upgrading of risk/overtreatment, especially in infants, as well as in order to identify tumours prone to developing homogeneous MNA.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

British Journal of Cancer

ISSN

0007-0920

e-ISSN

—

Svazek periodika

118

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

1502-1512

Kód UT WoS článku

000435643900012

EID výsledku v databázi Scopus

2-s2.0-85046792055